Immunopathology of Brucella infection

Recent Patents on Anti-Infective Drug Discovery

Volumn 8, Issue 1, 2013, Pages 18-26

  Baldi, Pablo C ^a   Giambartolomei, Guillermo H ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Immunogenetics Service   (Argentina)

Author keywords

Astrogliosis; Bacterial lipoproteins; Cytokines; Inflammation; Matrix metalloproteinases; Osteoclastogenesis; TLR2

Indexed keywords

ANTIBIOTIC AGENT; BRUCELLA VACCINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EXOTOXIN; GENTAMICIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTHRITIS; ARTICLE; ASTROCYTOSIS; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; BONE METABOLISM; BRUCELLA ABORTUS; BRUCELLOSIS; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FIBROBLAST LIKE SYNOVIOCYTE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NEUROBRUCELLOSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOARTICULAR BRUCELLOSIS; OSTEOCLASTOGENESIS; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; SYNOVIOCYTE;

ANIMALS; BRUCELLA; BRUCELLOSIS; CHEMOKINES; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MACROPHAGES; MICE; OSTEOBLASTS;

EID: 84875612415     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489113805290737     Document Type: Article

References (77)

1. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352: 2325-36.
2. Madkour MM. In: Madkour MM, Ed. Madkour's Brucellosis, 2nd ed. Berlin-Heidelberg: Springer-Verlag 2001: 74-84.
3. Young EJ. In: Young EJ and Corbel MJ, Eds. Brucellosis: clinical and laboratory aspects. Boca Raton, Florida: CRC Press 1989: 97-126.
4. Bouza E, García de la Torre M, Parras F, Guerrero A, Rodríguez-Créixems M, Gobernado J. Brucellar meningitis. Rev Infect Dis 1987; 9: 810-22.
5. Akritidis N, Tzivras M, Delladetsima I, Stefanaki S, Moutsopoulos HM, Pappas G. The liver in brucellosis. Clin Gastroenterol Hepatol 2007; 5: 1109-12.
6. Moreno E, Moriyón I. Brucella melitensis: A nasty bug with hidden credentials for virulence. Proc Natl Acad Sci USA 2002; 99: 1-3.
7. Chain PS, Comerci DJ, Tolmasky ME, Larimer FW, Malfatti SA, Vergez LM, et al. Whole-genome analyses of speciation events in pathogenic Brucellae. Infect Immun 2005; 73: 8353-61.
8. Oliveira SC, de Oliveira FS, Macedo GC, de Almeida LA, Carvalho NB. The role of innate immune receptors in the control of Brucella abortus infection: Toll-like receptors and beyond. Microbes Infect 2008; 10: 1005-9.
9. Berman DT, Kurtz RS. Relationship of biological activities to structure of Brucella abortus endotoxin and lipopolysaccharide. Ann Inst Pasteur Microbiol 1987; 138: 98-101.
10. Qureshi N, Takayama K, Seydel U, Wang R, Cotter J, Agrawall PK, et al. Structural analysis of lipid A derived from the lipopolysaccharide of Brucella abortus. J Endotoxin Res 1994; 1: 137-48.
11. Moreno E, Berman DT, Boettcher LA. Biological activities of Brucella abortus lipopolysaccharides. Infect Immun 1981; 31: 362-70.
12. Goldstein J, Hoffman T, Frasch C, Lizzio EF, Beining PR, Hochstein D, et al. Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect Immun 1992; 60: 1385-9.
13. Giambartolomei GH, Zwerdling A, Cassataro J, Bruno L Fossati CA, Philipp MT. Lipoproteins, not lipopolysaccharide, are the key mediators of the pro-inflammatory response elicited by heat-killed Brucella abortus. J Immunol 2004; 173: 4635-42.
14. Tibor A, Weynants V, Denoel P, Lichtfouse B, De Bolle X, Saman E, et al. Molecular cloning, nucleotide sequence, and occurrence of a 16.5-kilodalton outer membrane protein of Brucella abortus with similarity to pal lipoproteins. Infect Immun 1994; 62: 3633-9.
15. Tibor A, Saman E, de Wergifosse P, Cloeckaert A, Limet JN, Letesson JJ. Molecular characterization, occurrence, and immunogenicity in infected sheep and cattle of two minor outer membrane proteins of Brucella abortus. Infect Immun 1996; 64: 100-7.
16. Tibor A, Decelle B, Letesson JJ. Outer membrane proteins Omp10, Omp16, and Omp19 of Brucella spp. are lipoproteins. Infect Immun 1999; 67: 4960-2.
17. Seidel G, Pardo CA, Newman-Toker D, Olivi A, Eberhart CG. Neurobrucellosis presenting as leukoencephalophaty. The role of cytotoxic T lymphocytes. Arch Pathol Lab Med 2003; 127: 374-7.
18. Krishnan C, Kaplin AI, Graber JS, Darman JS, Kerr DA. Recurrent transverse myelitis following neurobrucellosis: Immunologic features and beneficial response to immunosuppression. J Neurovirol 2005; 11: 225-31.
19. Adams LG. The pathology of brucellosis reflects the outcome of the battle between the host genome and the Brucella genome. Vet Microbiol 2002; 90: 553-61.
20. Henning LN, Miller SM, Pak DH, Lindsay A, Fisher DA, Barnewall RE, et al. Pathophysiology of the rhesus macaque model for inhalational brucellosis. Infect Immun 2012; 80: 298-310.
21. Yingst SL, Huzella LM, Chuvala L, Wolcott M. A rhesus macaque (Macaca mulatta) model of aerosol-exposure brucellosis (Brucella suis): Pathology and diagnostic implications. J Med Microbiol 2010; 59: 724-30.
22. Silva TM, Costa EA, Paixão TA, Tsolis RM, Santos RL. Laboratory animal models for brucellosis research. J Biomed Biotechnol 2011; 2011: 518323
23. Sengupta D, Koblansky A, Gaines J, Brown T, West AP, Zhang D, et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J Immunol 2010; 184: 956-64
24. Salcedo SP, Marchesini MI, Lelouard H, Fugier E, Jolly G, Balor S, et al. Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1. PLoS Pathog 2008; 4: e21.
25. Madkour MM, Sharif H. In: Madkour MM, Ed. Madkour's Brucellosis, 2nd ed. Berlin-Heidelberg: Springer-Verlag 2001: 90-132.
26. Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15: 527-44.
27. Haynes DR. Bone lysis and inflammation. Inflamm Res 2004; 53: 596-600.
28. Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49-60.
29. Marriott I. Osteoblast responses to bacterial pathogens. A previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol Res 2004; 30: 291-308.
30. Delpino MV, Fossati CA, Baldi PC. Proinflammatory response of osteoblastic cell lines, and osteoblast-monocyte interaction upon infection with Brucella. Infect Immun 2009; 77: 984-95.
31. Scian R, Barrionuevo P, Giambartolomei GH, Fossati CA, Baldi PC, Delpino MV. GM-CSF-and TNF-PP-mediated matrix metalloproteinase production by human osteoblasts and monocytes upon infection with Brucella abortus. Infect Immun 2011; 79: 192-202.
32. Wallach JC, Delpino MV, Scian R, Deodato B, Fossati CA, Baldi PC. Prepatellar bursitis due to Brucella abortus: Case report and analysis of the local immune response. J Med Microbiol 2010; 59:1514-18.
33. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11: 529-43.
34. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: A key player in inflammation and joint destruction. Clin Immunol 2005; 115: 118-28.
35. Scian R, Barrionuevo P, Giambartolomei GH, De Simone EA, Vanzulli SI, Fossati CA, et al. Potential role of fibroblast-like synoviocytes in joint damage induced by Brucella abortus infection through the production and induction of matrix metalloproteinases. Infect Immun 2011; 79: 3619-32.
36. Aydin M, Fuat Yapar A, Savas L, Reyhan M, Pourbagher A, Turunc TY, et al. Scintigraphic findings in osteoarticular brucellosis. Nucl Med Commun 2005; 26:639-47.
37. Colmenero JD, Ruiz-Mesa JD, Plata A, Bermudez P, Martin-Rico P, Queipo-Ortuno MI, et al. Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis. Clin Infect Dis 2008; 46: 426-33.
38. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 2001; 232: 235-47.
39. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999; 154: 203-10.
40. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 1996: 64: 2371-80.
41. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282-90.
42. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.
43. Adamopoulos IE, Sabokbar A, Wordsworth BP, Carr A, Ferguson DJ, Athanasou NA. Synovial fluid macrophages are capable of osteoclast formation and resorption. J Pathol 2006; 208: 35-43.
44. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31: 653-61.
45. Delpino MV, Barrionuevo P, Costa Macedo G, Oliveira SC, Di Genaro S, Scian R, et al. Macrophage-elicited osteoclastogenesis in response to Brucella abortus infection requires TLR2/MyD88-dependent TNF-α production. J Leukoc Biol 2012; 91: 285-98.
46. Habeeb YK, Al-Najdi AK, Sadek SA, Al-Onaizi E. Paediatric neurobrucellosis: Case report and literature review. J Infect 1998; 37: 59-62.
47. Wallach JC, Baldi PC, Fossati CA. Clinical and diagnostic aspects of relapsing meningoencephalitis due to Brucella suis. Eur J Clin Microbiol Infect Dis 2002; 21: 760-2.
48. McLean DR, Russell N, Khan MY. Neurobrucellosis: Clinical and therapeutic features. Clin Infect Dis 1992; 15: 582-90.
49. Debono JE. Brucellosis simulating acute anterior poliomyelitis. Lancet 1964; 13: 1132-3.
50. Spink WW. The nature of brucellosis. Minneapolis, Mn: University of Minnesota Press. 1955.
51. Martinez-Chamorro E, Munoz A, Esparza J, Muñoz MJ, Giangaspro E. Focal cerebral involvement by neurobrucellosis: pathological and MRI findings. Eur J Radiol 2002; 43: 28-30.
52. Rangel Guerra R, Martinez HR, de Leon Flores L. [Neurobrucellosis. Report of five cases and literature review (author's transl)]. Rev Invest Clin 1982; 34: 62-8.
53. Giambartolomei GH, Wallach JC, Baldi PC. In: Halperin J., Ed. Encephalitis: Diagnosis and Treatment. New York: The Egerton Group 2008: 255-72.
54. Baldi PC, Araj GF, Racaro GC, Wallach JC, Fossati CA. Detection of antibodies to Brucella cytoplasmic proteins in the cerebrospinal fluid of patients with neurobrucellosis. Clin Diagn Lab Immunol 1999; 6: 756-9.
55. García Samartino C, Delpino MV, Pott Godoy C, Di Genaro MS, Pasquevich KA, Zwerdling A, et al. Brucella abortus induces the secretion of pro-inflammatory mediators from glial cells leading to astrocyte apoptosis. Am J Pathol 2010; 176:1323-38.
56. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178: 1771-5.
57. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni lipopolysaccharides and the development of Guillain-Barré syndrome. J Infect Dis 1998; 178: 1549-50.
58. Rees J, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-9.
59. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guiilain-Barré syndrome. Proc Natl Acad Sci USA 2004; 101: 11404-9.
60. Watanabe K, Kim S, Nishiguchi M, Suzuki H, Watarai M. Brucella melitensis infection associated with Guillain-Barre syndrome through molecular mimicry of host structures. FEMS Immunol Med Microbiol 2005; 45: 121-7.
61. Akhtar M. In: Madkour MM, Ed. Madkour's Brucellosis, 2nd ed. Berlin-Heidelberg: Springer-Verlag 2001: 65-73.
62. Nagore E, Sanchez-Motilla JM, Navarro V, Febrer MI, Aliaga A. Leukocytoclastic vasculitis as a cutaneous manifestation of systemic infection caused by Brucella melitensis. Cutis 1999; 63: 25-7.
63. Adaletli I, Albayram S, Gurses B, Ozer H, Yilmaz MH, Gulsen F, et al. Vasculopathic changes in the cerebral arterial system with neurobrucellosis. AJNR Am J Neuroradiol 2006; 27: 384-6.
64. Reguera JM, Alarcón A, Miralles F, Pachón J, Juárez C, Colmenero JD. Brucella endocarditis: Clinical, diagnostic, and therapeutic approach. Eur J Clin Microbiol Infect Dis 2003; 22: 647-50.
65. Aguado JM, Barros C, Gomez Garces JL, Fernández-Guerrero ML. Infective aortitis due to Brucella melitensis. Scand J Infect Dis 1987; 19: 483-4.
66. Moreillon P, Que YA, Bayer AS. Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am 2002; 16: 297-318.
67. Müller AM, Cronen C, Kupferwasser LI, Oelert H, Müller KM, Kirkpatrick CJ. Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. J Pathol 2000; 191: 54-60.
68. Ferrero MC, Bregante J, Delpino MV, Barrionuevo P, Fossati CA, Giambartolomei GH, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect 2011; 13: 852-61.
69. Chorianopoulos E, Bea F, Katus HA, Frey N. The role of endothelial cell biology in endocarditis. Cell Tissue Res 2009; 335: 153-63.
70. Benoit M, Thuny F, Le Priol Y, Lepidi H, Bastonero S, Casalta JP, et al. The transcriptional programme of human heart valves reveals the natural history of infective endocarditis. PLoS One 2010; 5: e8939.
71. Estein SM, Fiorentino MA, Paolicchi FA, Clausse M, Manazza J, Cassataro J, et al. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine 2009; 27: 6704-11.
72. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 2007; 25: 4437-46.
73. Goldbaum, F.A. Isolated chimeric proteins of modified lumazine synthase. WO2005121330 (2005).
74. Jenner, D.C., Atkins, H.S. Vaccine for brucellosis. US20110033492A1 (2011).
75. Sergeevich, B.V., Grigor'evich, O.V., Nikolaevich, L.V., Vladislavovna L.O., Gavrilovna, P.T., Vital'evna, G:T., Alekseevich N.A. Method for producing protective antigen brucella complex. RU2008150696 (2010)
76. Nora, V.R., Santiago, S.V., Jauma, V.M., Elisa, E.S.D.V., Maria Jose, B.P., David, G.F., Edurne, I.I. Use of ionic complex of gentamicin: AOT fort he treatment of brucellosis. WO2009071731A1 (2009)
77. Maletskaja, O.V., Taran, T.V., Efremenko V.I., Ljamkin, G.I., Sokolova, I.A., Ljapustina, L. Method for treatment of brocellosis. RU2234311C1 (2004).